MX9605365A - Fracciones polipeptidicas solubles de la proteina lag-3; procedimiento de produccion; composicion terapeutica y anticuerpos ant-idiotipo. - Google Patents

Fracciones polipeptidicas solubles de la proteina lag-3; procedimiento de produccion; composicion terapeutica y anticuerpos ant-idiotipo.

Info

Publication number
MX9605365A
MX9605365A MX9605365A MX9605365A MX9605365A MX 9605365 A MX9605365 A MX 9605365A MX 9605365 A MX9605365 A MX 9605365A MX 9605365 A MX9605365 A MX 9605365A MX 9605365 A MX9605365 A MX 9605365A
Authority
MX
Mexico
Prior art keywords
lag
production
soluble polypeptide
therapeutic composition
idiotype antibody
Prior art date
Application number
MX9605365A
Other languages
English (en)
Inventor
Florence Faure
Thierry Hercend
Bertrand Huard
Frederic Triebel
Original Assignee
Roussy Inst Gustave
Inst Nat Sante Rech Med
Applied Research Systems
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Roussy Inst Gustave, Inst Nat Sante Rech Med, Applied Research Systems filed Critical Roussy Inst Gustave
Publication of MX9605365A publication Critical patent/MX9605365A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Abstract

La invencion se refiere a una fraccion polipeptídica soluble constituida por todo o parte de al menos uno de los cuatro dominios extracelulares del tipo inmunoglobulina de la proteína LAG-3 (aminoácido 1 al 159, 160 al 239 al 330, 331 al 412 de la secuencia SEQ ID No. 1) o por una secuencia peptídica que se deriva de los dominios mediante reemplazo, adicion y/o supresion de uno o varios aminoácidos, y porque posee una especificidad al menos igual a aquella de LAG-3 para su ligando.
MX9605365A 1994-05-06 1995-05-05 Fracciones polipeptidicas solubles de la proteina lag-3; procedimiento de produccion; composicion terapeutica y anticuerpos ant-idiotipo. MX9605365A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR9405643 1994-05-06
PCT/FR1995/000593 WO1995030750A2 (fr) 1994-05-06 1995-05-05 Fractions polypeptidiques solubles de la proteine lag-3; procede de production; composition therapeutique; anticorps anti-idiotype

Publications (1)

Publication Number Publication Date
MX9605365A true MX9605365A (es) 1997-12-31

Family

ID=9463004

Family Applications (1)

Application Number Title Priority Date Filing Date
MX9605365A MX9605365A (es) 1994-05-06 1995-05-05 Fracciones polipeptidicas solubles de la proteina lag-3; procedimiento de produccion; composicion terapeutica y anticuerpos ant-idiotipo.

Country Status (18)

Country Link
US (3) US5955300A (es)
EP (1) EP0758383B1 (es)
JP (1) JP3700859B2 (es)
KR (1) KR100257466B1 (es)
CN (1) CN1110557C (es)
AT (1) ATE352617T1 (es)
BR (1) BR9507618A (es)
CA (1) CA2189657C (es)
DE (1) DE69535375T2 (es)
DK (1) DK0758383T3 (es)
ES (1) ES2281899T3 (es)
IL (1) IL113617A (es)
MX (1) MX9605365A (es)
NO (1) NO325828B1 (es)
PT (1) PT758383E (es)
RU (1) RU2178306C2 (es)
WO (1) WO1995030750A2 (es)
ZA (1) ZA953629B (es)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2000508226A (ja) * 1995-07-21 2000-07-04 アプライド リサーチ システムズ アース ホールディング エヌ．ヴィ． Ｌａｇ−３タンパク質によるｔｈ１リンパ球を検出、同定、単離並びに選択的に標識およびターゲッティングする方法
WO1998023741A1 (fr) * 1996-11-28 1998-06-04 Institut Gustave Roussy Mutants de la proteine lag-3, leur expression et utilisation
WO1998023748A1 (en) * 1996-11-29 1998-06-04 Applied Research Systems Ars Holding N.V. Methods for preventing graft rejection in transplantation and for producing a universal gene therapy host cell using lymphocyte activation (lag-3)
EP0900841A1 (en) * 1997-06-18 1999-03-10 Institut National De La Sante Et De La Recherche Medicale (Inserm) LAG-3 splice variants
EP0893507A1 (en) * 1997-07-25 1999-01-27 Institut Gustave Roussy Use of MHC class II ligands (CD4 and LAG-3) as adjuvant for vaccination and of LAG-3 in cancer treatment
US6660843B1 (en) * 1998-10-23 2003-12-09 Amgen Inc. Modified peptides as therapeutic agents
US6434012B2 (en) * 2000-02-11 2002-08-13 Tyco Electronics Logistics Ag Circuit board interconnect
EP1278778A2 (en) * 2000-05-03 2003-01-29 Amgen Inc., Modified peptides, comprising an fc domain, as therapeutic agents
EP1575480A4 (en) * 2002-02-22 2008-08-06 Genentech Inc COMPOSITIONS AND METHODS FOR TREATING DISEASES RELATED TO THE IMMUNE SYSTEM
SI1897548T1 (sl) * 2003-02-28 2013-12-31 The Johns Hopkins University Regulacija celic T
FR2868781B1 (fr) * 2004-04-13 2008-02-22 Immutep Composition de vaccin comprenant un ligand cmh de classe ii couple a un antigene, procede de preparation et utilisations
EP2044949A1 (en) 2007-10-05 2009-04-08 Immutep Use of recombinant lag-3 or the derivatives thereof for eliciting monocyte immune response
AR072999A1 (es) 2008-08-11 2010-10-06 Medarex Inc Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3) y los usos de estos
AR091649A1 (es) 2012-07-02 2015-02-18 Bristol Myers Squibb Co Optimizacion de anticuerpos que se fijan al gen de activacion de linfocitos 3 (lag-3) y sus usos
AU2014323523B2 (en) 2013-09-20 2020-02-20 Bristol-Myers Squibb Company Combination of anti-LAG-3 antibodies and anti-PD-1 antibodies to treat tumors
GB201322626D0 (en) 2013-12-19 2014-02-05 Immutep S A Combined preparations for the treatment of cancer
JOP20200094A1 (ar) 2014-01-24 2017-06-16 Dana Farber Cancer Inst Inc جزيئات جسم مضاد لـ pd-1 واستخداماتها
KR20220126813A (ko) 2014-03-14 2022-09-16 노파르티스 아게 Lag-3에 대한 항체 분자 및 그의 용도
US10155818B2 (en) 2014-05-28 2018-12-18 Agenus Inc. Anti-GITR antibodies and methods of use thereof
TWI693232B (zh) 2014-06-26 2020-05-11 美商宏觀基因股份有限公司 與pd-1和lag-3具有免疫反應性的共價結合的雙抗體和其使用方法
JO3663B1 (ar) 2014-08-19 2020-08-27 Merck Sharp & Dohme الأجسام المضادة لمضاد lag3 وأجزاء ربط الأنتيجين
GB201500374D0 (en) 2015-01-09 2015-02-25 Immutep S A Combined preparations for the treatment of cancer
MA41463A (fr) * 2015-02-03 2017-12-12 Anaptysbio Inc Anticorps dirigés contre le gène d'activation 3 des lymphocytes (lag-3)
TWI773646B (zh) 2015-06-08 2022-08-11 美商宏觀基因股份有限公司 結合lag-3的分子和其使用方法
BR112018000903A2 (pt) 2015-07-16 2018-09-11 Biokine Therapeutics Ltd. composições e métodos para o tratamento de câncer
KR20180093127A (ko) 2015-07-30 2018-08-20 마크로제닉스, 인크. Pd-1-결합 분자 및 그것의 사용 방법
US20180230431A1 (en) 2015-08-07 2018-08-16 Glaxosmithkline Intellectual Property Development Limited Combination Therapy
TWI756187B (zh) 2015-10-09 2022-03-01 美商再生元醫藥公司 抗ｌａｇ３抗體及其用途
CN108366548B (zh) 2015-11-20 2021-10-08 瑞泽恩制药公司 具有人源化淋巴细胞活化基因3的非人动物
MX2018006477A (es) 2015-12-02 2018-09-03 Agenus Inc Anticuerpos y metodos de uso de estos.
US10954301B2 (en) 2015-12-14 2021-03-23 Macrogenics, Inc. Bispecific molecules having immunoreactivity with PD-1 and CTLA-4, and methods of use thereof
WO2017106129A1 (en) 2015-12-16 2017-06-22 Merck Sharp & Dohme Corp. Anti-lag3 antibodies and antigen-binding fragments
IL260743B2 (en) * 2016-02-04 2024-03-01 Trianni Inc Advanced production of antibodies
CN109475603B (zh) 2016-06-20 2023-06-13 科马布有限公司 抗pd-l1抗体
JP6998895B2 (ja) 2016-06-23 2022-01-18 江蘇恒瑞医薬股▲ふん▼有限公司 Ｌａｇ－３抗体、その抗原結合フラグメント、およびそれらの医薬的用途
US10844119B2 (en) 2016-10-11 2020-11-24 Agenus Inc. Anti-LAG-3 antibodies and methods of use thereof
UA127050C2 (uk) 2016-10-13 2023-03-29 Чіа Тай Тяньцин Фармасьютікал Груп Ко., Лтд. Ahtи-lag-3 антитіло i композиція, що містить його
UY37463A (es) 2016-11-02 2018-05-31 Glaxosmithkline Ip No 2 Ltd Proteínas de unión
CN110650974B (zh) 2017-02-10 2024-04-19 瑞泽恩制药公司 用于免疫-pet成像的放射性标记的抗-lag3抗体
CA3185303A1 (en) 2017-04-05 2018-10-11 Symphogen A/S Combination therapies targeting pd-a, tim-3, and lag-3
EP3621642A4 (en) * 2017-05-10 2021-01-06 Centrymed Pharmaceutical Inc HUMAN MONOCLONAL ANTIBODIES AGAINST LAG3 AND THEIR USES
BR112019021847A2 (pt) 2017-05-30 2020-06-02 Bristol-Myers Squibb Company Composições compreendendo um anticorpo anti-lag-3 ou um anticorpo anti-lag-3 e um anticorpo anti-pd-1 ou anti-pd-l1
BR112019020610A2 (pt) 2017-05-30 2020-04-22 Bristol-Myers Squibb Company tratamento de tumores positivos para o lag-3
KR20200042937A (ko) 2017-08-30 2020-04-24 페인스 테라퓨틱스 인코포레이티드 항-lag-3 항체 및 이의 용도
JP2021506922A (ja) 2017-12-22 2021-02-22 江蘇恒瑞医薬股▲ふん▼有限公司 Ｌａｇ−３抗体医薬組成物およびその使用
CN113825527A (zh) 2019-05-13 2021-12-21 瑞泽恩制药公司 用于在治疗癌症中增强效力的pd-1抑制剂和lag-3抑制剂的组合
CN112010972B (zh) * 2019-05-31 2023-01-10 瑞阳(苏州)生物科技有限公司 与人lag-3蛋白结合的抗体及其编码基因和应用
CN110950966B (zh) * 2019-12-13 2020-12-11 启辰生生物科技(珠海)有限公司 融合蛋白、编码核酸和细胞及用途

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0325224B1 (en) 1988-01-22 1996-07-31 ZymoGenetics, Inc. Methods of producing secreted receptor analogs
US5116964A (en) 1989-02-23 1992-05-26 Genentech, Inc. Hybrid immunoglobulins
FR2656800B1 (fr) 1990-01-08 1992-05-15 Roussy Inst Gustave Nouvelles proteines produits par les lymphocytes humains, sequence d'adn codant pour ces proteines et applications pharmaceutiques et biologiques.
US5976877A (en) 1990-01-08 1999-11-02 Institut National De La Sante Et De La Recherche Medicale (Inserm) Proteins produced by human lymphocytes DNA sequence encoding these proteins and their pharmaceutical and biological uses
CA2086325C (en) 1990-07-02 2010-10-05 Peter S. Linsley Ligand for cd28 receptor on b cells and methods

Also Published As

Publication number Publication date
CN1155904A (zh) 1997-07-30
US5955300A (en) 1999-09-21
NO325828B1 (no) 2008-07-28
EP0758383B1 (fr) 2007-01-24
DE69535375T2 (de) 2007-11-08
AU2570195A (en) 1995-11-29
WO1995030750A3 (fr) 1995-12-21
WO1995030750A8 (fr) 1999-07-29
CA2189657C (fr) 2002-03-12
ZA953629B (en) 1996-11-05
EP0758383A1 (fr) 1997-02-19
ATE352617T1 (de) 2007-02-15
BR9507618A (pt) 1997-08-19
CN1110557C (zh) 2003-06-04
CA2189657A1 (fr) 1995-11-16
WO1995030750A2 (fr) 1995-11-16
KR100257466B1 (ko) 2000-07-01
JPH09508023A (ja) 1997-08-19
NO964650D0 (no) 1996-11-04
DE69535375D1 (de) 2007-03-15
JP3700859B2 (ja) 2005-09-28
ES2281899T3 (es) 2007-10-01
NO964650L (no) 1997-01-06
PT758383E (pt) 2007-05-31
IL113617A (en) 2007-09-20
AU708825B2 (en) 1999-08-12
US6143273A (en) 2000-11-07
IL113617A0 (en) 1995-08-31
KR970702917A (ko) 1997-06-10
USRE38313E1 (en) 2003-11-11
DK0758383T3 (da) 2007-05-29
RU2178306C2 (ru) 2002-01-20

Similar Documents

Publication Publication Date Title
MX9605365A (es) Fracciones polipeptidicas solubles de la proteina lag-3; procedimiento de produccion; composicion terapeutica y anticuerpos ant-idiotipo.
BG102983A (en) Extramembrane protein 106 polypeptide of moraxella catarrhalis, its gene sequence and application
IL134982A0 (en) Antibodies which react with polypeptides of cd-44 surface proteins and diagnostic and pharmaceutical compositions prepared therewith
ATE430801T1 (de) Von wd-40 abstammende peptide und ihre verwendung
IL128829A0 (en) Improved solid-phase peptide and agent for use in such synthesis
DK1129186T3 (da) Et faktor VIII-polypeptid med faktor VIII:C-aktivitet
EP1282722A4 (en) STABILIZED PROTEINS
DE69926627D1 (de) Insulinartigen wachstumsfaktor bindendes protein -3 variante
ATE223481T1 (de) Peptid der löslichen form von acetylcholinesterase mit aktivität als calciumkanalmodulator
DE3261304D1 (en) Retro-inverso analogues of c-terminal penta and hexapeptides of substance p.
EA201001190A1 (ru) Выделенное антитело, специфически связанное с полипептидом, состоящее из последовательности аминокислотных остатков
DE69333952D1 (de) Klonering von dem gen für das t gondii protein gp 28.5 peptidfragmente aus diesem protein und ihre verwendungen.
GB9509557D0 (en) PCNA binding substance
GB9416536D0 (en) Orphan receptor
AU2676399A (en) Novel cystine knot protein and materials and methods for making it
MX9606720A (es) Polipeptidos con dominios de enlace al receptor 1 de la interleucina 8(il8r1).

Legal Events

Date Code Title Description
FG Grant or registration
GB Transfer or rights